Beta Drugs Q3 Results
- BSE: -
- NSE: BETA
- ISIN: INE351Y01019
- Sector: Biotechnology & Drugs
BSE
This stock is not traded on BSE
NSE
2,130
44.20 (2.12%)
44.20 (2.12%)Volume18.07 K
Updated: Fri 11 Sep, 2026 | 15:29:46
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Quarter ended Dec 25
Note: Comparison is on QoQ basis
Quarterly - Beta Drugs Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 22 | QoQ Comp |
|---|---|---|---|
| Total Operating Expense | 74.67 | 90.42 | -13.49% |
| Depreciation/ Amortization | 4.39 | 4.83 | 3.52% |
| Operating Income | 12.60 | 21.97 | -26.20% |
| Net Income | 8.52 | 15.83 | -30.29% |
| Other Operating Expenses Total | 17.42 | 9.30 | 6.85% |
| Net Income Before Taxes | 10.47 | 21.16 | -36.32% |
| Total Revenue | 87.27 | 112.39 | -15.59% |
| Selling/ General/ Admin Expenses Total | 16.82 | 10.94 | 2.06% |
| Diluted Normalized EPS | 8.40 | 16.47 | -30.58% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.